Protherics PLC announces Interest in Shares

CHESHIRE, UK , the international biopharmaceutical company focused on critical care and cancer, announces that on 3 July 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies ("AXA"). The notification follows a disposal of voting rights. Details of the interest notified are as follows: 1. Reason for the notification (please tick the appropriate box or boxes) A disposal of voting rights X An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights Other (please specify): 2. Full name of person(s) subject to the AXA S.A., 25 Avenue Matignon, notification obligation: 75008 Paris and its group of companies. 3. Full name of shareholder(s) (if different from 2.): 4. Date of the transaction (and date on 2 July 2008 which the threshold is crossed or reached if different): 5. Date on which issuer notified: 3 July 2008 6. Threshold(s) that is/are crossed or 13% reached: 7. Notified details: A: Voting rights attached to shares Class/ Situation previous to Resulting situation after the triggering type of the Triggering transaction shares transaction if Number of Number of Number Number of voting % of voting possible Shares Voting of rights rights using Rights shares the ISIN CODE Direct Direct Indirect Direct Indirect 0702920 44,836,830 44,836,830 941,666 941,666 40,774,831 0.28% 11.98% B: Financial Instruments Resulting situation after the triggering transaction Type of Expiration Exercise/ Number of voting rights that % of financial date Conversion may be acquired if the voting instrument Period/ instrument is exercised/ rights Date converted. Total (A+B) Number of voting rights % of voting rights 41,716,497 12.25% 8. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable : Name of Company/Fund Number of % of issued share Shares capital AXA UK Investment Co ICVC 552,143 0.16220 UK Smaller Companies Fund Indirect Sun Life Pensions Management Ltd 225,000 0.06610 DirectSun Life Unit Assurance Ltd 53,913 0.01584 FTSE All Share Tracker Direct Sun Life Pensions Management 294,874 0.08662 FTSE All Share Tracker Direct AXA Framlington 425,000 0.12485 Indirect AXA Framlington 1,851,468 0.54388 Indirect AXA Framlington 1,909,918 0.56105 Indirect AXA Framlington 459,865 0.13509 Indirect AXA Framlington 639,353 0.18781 Indirect AXA Framlington 15,438,453 4.53516 Indirect AXA Framlington 13,753,131 4.04008 Indirect AXA Framlington 2,000,000 0.58751 Indirect AXA Framlington 1,500,000 0.44064 Indirect AXA Framlington 500,000 0.14688 Indirect AXA Framlington 220,000 0.06463 Indirect Framlington onshore private 975,500 0.28656 clients Indirect AXA Sun Life ith Profits Passive 226,817 0.06663 Direct AXA Sun Life With Profits 141,062 0.04144 Passive Direct AXA Framlington 550,000 0.16157 Indirect Total Direct 941,666 0.27662 Total Indirect 40,774,831 11.97790 TOTAL 41,716,497 12.25452 Proxy Voting: 9. Name of the proxy holder: 10. Number of voting rights proxy holder will cease to hold: 11. Date on which proxy holder will cease to hold voting rights: 12. Additional information: / Ends / For further information please contact: Protherics Nick Staples, Director of Corporate Affairs [phone] Julie Vickers, Company Secretary [phone] Financial Dynamics - press enquiries London: Ben Atwell, Lara Mott [phone] New York: John Capodanno [phone] Or visit www.protherics.com This information is provided by RNS The company news service from the London Stock Exchange END

Contacts: RNS Customer Services 0044-207797-4400 Email Contact http://www.rns.com